Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 6/20 | 0.35 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.35 |
| ▸ | S1PR5 | Q9H228 | 4/20 | 0.35 |
| ▸ | SRC | P12931 | 2/20 | 0.35 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.34 |
| ▸ | GCG | P01275 | 1/20 | 0.33 |
| ▸ | GCGR | P47871 | 1/20 | 0.33 |
| ▸ | GIPR | P48546 | 1/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2445954 | 1.00 | HRH3 (0.38) | HRH3TRPV1KCNH2S1PR1S1PR4 | |
| SCHEMBL2453803 | 0.87 | S1PR1 (0.37) | HRH3TRPV1KCNH2S1PR1S1PR4 | |
| SCHEMBL2453805 | 0.87 | S1PR1 (0.37) | HRH3TRPV1KCNH2S1PR1S1PR4 | |
| SCHEMBL2453802 | 0.87 | S1PR1 (0.37) | HRH3TRPV1KCNH2S1PR1S1PR4 | |
| SCHEMBL2439689 | 0.85 | KCNH2 (0.42) | HRH3TRPV1KCNH2SRCNPC1L1 | |
| SCHEMBL2439690 | 0.85 | KCNH2 (0.42) | HRH3TRPV1KCNH2SRCNPC1L1 | |
| SCHEMBL2441337 | 0.82 | KCNH2 (0.40) | TRPV1KCNH2S1PR1S1PR4S1PR5 | |
| SCHEMBL2441346 | 0.82 | KCNH2 (0.40) | TRPV1KCNH2S1PR1S1PR4S1PR5 | |
| SCHEMBL2441341 | 0.82 | KCNH2 (0.40) | TRPV1KCNH2S1PR1S1PR4S1PR5 | |
| SCHEMBL11030116 | 0.81 | TRPV1 (0.42) | HRH3TRPV1KCNH2SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10081646-B2 | Heterobicyclic sphingosine 1-phosphate analogs | BIOGEN MA INC. (US) | 2018-09-25 | — | — | US | disclosed |
| US-20180002356-A1 | HETEROBICYCLIC SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN MA INC. | 2018-01-04 | — | — | US | disclosed |
| US-9708353-B2 | Heterobicyclic sphingosine 1-phosphate analogs | BIOGEN MA INC. (US) | 2017-07-18 | — | — | US | disclosed |
| EP-2364089-B1 | HETEROBICYCLIC SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN MA INC (US) | 2016-12-07 | — | — | EP | disclosed |
| US-9181191-B2 | Heterobicyclic sphingosine 1-phosphate analogs | BIOGEN MA INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150232492-A1 | HETEROBICYCLIC SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN MA INC. | 2015-08-20 | — | — | US | disclosed |
| US-20140100195-A1 | Heterobicyclic sphingosine 1-phosphate analogs | BIOGEN MA INC. | 2014-04-10 | — | — | US | disclosed |
| US-8349849-B2 | Heterobicyclic sphingosine 1-phosphate analogs | BIOGEN IDEC MA INC. (US) | 2013-01-08 | — | — | US | disclosed |
| EP-2364089-A1 | HETEROBICYCLIC SPHINGOSINE 1-PHOSPHATE ANALOGS | Biogen Idec MA Inc. (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20100160357-A1 | Heterobicyclic sphingosine 1-phosphate analogs | BIOGEN MA INC. | 2010-06-24 | — | — | US | disclosed |
| WO-2010051031-A1 | HETEROBICYCLIC SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN IDEC MA INC. (US) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180002356-A1 | HETEROBICYCLIC SPHINGOSINE 1-PHOSPHATE ANALOGS | S1PR1, S1PR2, S1PR4 | HRH3 541/4885TRPV1 589/4885KCNH2 3308/4885 |
| US-20150232492-A1 | HETEROBICYCLIC SPHINGOSINE 1-PHOSPHATE ANALOGS | S1PR1, S1PR2, S1PR4 | HRH3 541/4885TRPV1 589/4885KCNH2 3308/4885 |
| US-20140100195-A1 | Heterobicyclic sphingosine 1-phosphate analogs | S1PR1, S1PR2, S1PR4 | HRH3 541/4885TRPV1 589/4885KCNH2 3308/4885 |
| US-20100160357-A1 | Heterobicyclic sphingosine 1-phosphate analogs | S1PR1, S1PR2, S1PR4 | HRH3 541/4885TRPV1 589/4885KCNH2 3308/4885 |
| US-10081646-B2 | Heterobicyclic sphingosine 1-phosphate analogs | S1PR1, S1PR2, S1PR4 | HRH3 541/4885TRPV1 589/4885KCNH2 3308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.